Baseline analytes and bleeding outcomes
| Baseline assays and future bleeding (activated subjects) . | No WHO grade 2+ bleeding . | WHO grade 2+ bleeding . | P value . | |
|---|---|---|---|---|
| Platelets × 103/mm3 | N | 64 | 51 | |
| Mean (SD) | 20.5 (5) | 21 (9) | .72 | |
| Median (Q1, Q3) | 20 (17, 24) | 20 (17, 24) | ||
| Hematocrit % | N | 64 | 51 | |
| Mean (SD) | 28 (4.3) | 25.5 (2.5) | <.01 | |
| Median (Q1, Q3) | 28 (25, 30) | 25.7 (24, 27) | ||
| Serum creatinine (mg/dL) | N | 64 | 51 | |
| Mean (SD) | 0.7 (0.2) | 0.7 (0.2) | .64 | |
| Median (Q1, Q3) | 0.7 (0.6, 0.8) | 0.7 (0.5, 0.9) | ||
| ANC × 103/mm3 | N | 62 | 51 | |
| Mean (SD) | 0.2 (0.7) | 0.5 (1.1) | .21 | |
| Median (Q1, Q3) | 0 (0, 0.1) | 0 (0, 0.2) | ||
| Clauss fibrinogen (mg/dL) | N | 30 | 30 | |
| Mean (SD) | 400.7 (174.7) | 445.7 (151.1) | .29 | |
| Median (Q1, Q3) | 401.5 (279.2, 485.5) | 422 (335.5, 575.5) | ||
| D-dimer (μg/mL) | N | 64 | 51 | |
| Mean (SD) | 2 (5.1) | 1.6 (3.3) | .57 | |
| Median (Q1, Q3) | 0.9 (0.5, 1.9) | 0.8 (0.4, 1.4) | ||
| ECLT (h)∗ | N | 61 | 49 | |
| Mean (SD) | 20.6 (5.5) | 21.9 (2.9) | .11 | |
| Median (Q1, Q3) | 23.1 (18.9, 24.0) | 23.7 (21.2, 24.0) | ||
| tPA-CLT (h)∗ | N | 62 | 51 | |
| Mean (SD) | 3.5 (2.4) | 3.3 (1.9) | .53 | |
| Median (Q1, Q3) | 2.8 (2.3, 3.4) | 2.7 (2.3, 3.0) | ||
| Total PAI-1 (ng/mL) | N | 62 | 50 | |
| Mean (SD) | 24.2 (25.9) | 24.2 (23) | 1.00 | |
| Median (Q1, Q3) | 16 (9.1, 28.8) | 17.8 (7.3, 30.9) | ||
| tPA (IU/mL) | N | 62 | 50 | |
| Mean (SD) | 0.4 (0.6) | 0.3 (0.6) | .73 | |
| Median (Q1, Q3) | 0.2 (0.1, 0.4) | 0.1 (0.1, 0.3) | ||
| Plasminogen (μg/mL) | N | 57 | 37 | |
| Mean (SD) | 119.7 (76.8) | 115.2 (83.6) | .79 | |
| Median (Q1, Q3) | 97.7 (68.4, 161.9) | 78.4 (59.9, 139.9) | ||
| PAP complexes (μg/mL) | N | 57 | 37 | |
| Mean (SD) | 1.2 (1.1) | 1.1 (1) | .79 | |
| Median (Q1, Q3) | 0.8 (0.5, 1.5) | 0.8 (0.5, 1.4) | ||
| Α2AP (μg/mL) | N | 57 | 37 | |
| Mean (SD) | 223.1 (191) | 250.4 (211.5) | .53 | |
| Median (Q1, Q3) | 179.8 (102, 277) | 180.9 (100.4, 333.7) | ||
| Baseline assays and future bleeding (activated subjects) . | No WHO grade 2+ bleeding . | WHO grade 2+ bleeding . | P value . | |
|---|---|---|---|---|
| Platelets × 103/mm3 | N | 64 | 51 | |
| Mean (SD) | 20.5 (5) | 21 (9) | .72 | |
| Median (Q1, Q3) | 20 (17, 24) | 20 (17, 24) | ||
| Hematocrit % | N | 64 | 51 | |
| Mean (SD) | 28 (4.3) | 25.5 (2.5) | <.01 | |
| Median (Q1, Q3) | 28 (25, 30) | 25.7 (24, 27) | ||
| Serum creatinine (mg/dL) | N | 64 | 51 | |
| Mean (SD) | 0.7 (0.2) | 0.7 (0.2) | .64 | |
| Median (Q1, Q3) | 0.7 (0.6, 0.8) | 0.7 (0.5, 0.9) | ||
| ANC × 103/mm3 | N | 62 | 51 | |
| Mean (SD) | 0.2 (0.7) | 0.5 (1.1) | .21 | |
| Median (Q1, Q3) | 0 (0, 0.1) | 0 (0, 0.2) | ||
| Clauss fibrinogen (mg/dL) | N | 30 | 30 | |
| Mean (SD) | 400.7 (174.7) | 445.7 (151.1) | .29 | |
| Median (Q1, Q3) | 401.5 (279.2, 485.5) | 422 (335.5, 575.5) | ||
| D-dimer (μg/mL) | N | 64 | 51 | |
| Mean (SD) | 2 (5.1) | 1.6 (3.3) | .57 | |
| Median (Q1, Q3) | 0.9 (0.5, 1.9) | 0.8 (0.4, 1.4) | ||
| ECLT (h)∗ | N | 61 | 49 | |
| Mean (SD) | 20.6 (5.5) | 21.9 (2.9) | .11 | |
| Median (Q1, Q3) | 23.1 (18.9, 24.0) | 23.7 (21.2, 24.0) | ||
| tPA-CLT (h)∗ | N | 62 | 51 | |
| Mean (SD) | 3.5 (2.4) | 3.3 (1.9) | .53 | |
| Median (Q1, Q3) | 2.8 (2.3, 3.4) | 2.7 (2.3, 3.0) | ||
| Total PAI-1 (ng/mL) | N | 62 | 50 | |
| Mean (SD) | 24.2 (25.9) | 24.2 (23) | 1.00 | |
| Median (Q1, Q3) | 16 (9.1, 28.8) | 17.8 (7.3, 30.9) | ||
| tPA (IU/mL) | N | 62 | 50 | |
| Mean (SD) | 0.4 (0.6) | 0.3 (0.6) | .73 | |
| Median (Q1, Q3) | 0.2 (0.1, 0.4) | 0.1 (0.1, 0.3) | ||
| Plasminogen (μg/mL) | N | 57 | 37 | |
| Mean (SD) | 119.7 (76.8) | 115.2 (83.6) | .79 | |
| Median (Q1, Q3) | 97.7 (68.4, 161.9) | 78.4 (59.9, 139.9) | ||
| PAP complexes (μg/mL) | N | 57 | 37 | |
| Mean (SD) | 1.2 (1.1) | 1.1 (1) | .79 | |
| Median (Q1, Q3) | 0.8 (0.5, 1.5) | 0.8 (0.5, 1.4) | ||
| Α2AP (μg/mL) | N | 57 | 37 | |
| Mean (SD) | 223.1 (191) | 250.4 (211.5) | .53 | |
| Median (Q1, Q3) | 179.8 (102, 277) | 180.9 (100.4, 333.7) | ||
tPA concentration = 0.6 nM.
ANC, absolute neutrophil count; A2AP, alpha2 antiplasmin; PAP, plasmin-α2 antiplasmin.
Measured for a maximum of 24 hours.